About This Field Notebook

What Freebase Peptides is

Freebase Peptides is a field notebook kept on three peptides studied for metabolic regulation and weight management: retatrutide, MOTS-c, and tesamorelin, with retatrutide as the lead. Its purpose is to make a scattered and frequently overstated literature legible — to set down, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence reaches.

The entries are grouped by mechanism: three compounds that each engage metabolism from a different structural level — receptor-driven incretin pharmacology (retatrutide), mitochondrial energy sensing (MOTS-c), and pituitary axis modulation (tesamorelin). Read together, the three notebook pages give a fuller view of the metabolic research landscape than any one alone. Each compound has its own page; a comparison page lines them up side by side; and a single shared references list gathers every source.

How it is compiled

A few working rules keep the notebook honest.

Everything traces to the peer-reviewed record. Each research claim carries a numbered citation — PubMed-indexed articles and reviews, with DOIs or PubMed/PMC links — gathered on the references page. A finding that comes from a review rather than a primary study is marked as such.

Evidence is logged at its true strength, never rounded up. Approval status is stated flatly: tesamorelin is FDA-approved for a specific and narrow indication; retatrutide is in Phase 3 trials; MOTS-c has no human efficacy trials at all. Doses appear only as they were studied — for example, "12 mg subcutaneously once weekly in a Phase 2 obesity RCT" — never extrapolated or dressed up as a recommendation. Where a result is from animals, or from a single study, or bounded to one population, the page says so.

And the three pages talk to each other. Because the same themes — insulin sensitivity, visceral fat, energy expenditure, the GH axis — recur across compounds, the entries cross-link so a reader can follow a mechanism from one peptide to the next.

What it is not

This is a notebook, not a storefront and not a practice. Freebase Peptides sells nothing and stocks nothing; it does not supply, source, or broker any peptide or research chemical, and it holds no affiliate or referral tie to any vendor. There is no clinical staff behind it — it does not diagnose, does not prescribe, and does not set out a dose, schedule, or route for any person, and nothing on it is medical advice.

The compounds written up here run the full regulatory gamut: an FDA-approved prescription drug for a specific indication (tesamorelin), an investigational Phase 3 compound (retatrutide), and a research chemical with no approved human use (MOTS-c). That gap matters — reading about a compound here is not the same as having access to clinical-grade material, clinical oversight, or a therapeutic indication. Anyone seeking guidance about a metabolic condition should consult a licensed clinician in their own jurisdiction, working from regulated, evidence-based options.